

United States of America

United States Patent and Trademark Office



Reg. No. 7,095,521

Registered Jul. 04, 2023

Corrected Nov. 21, 2023

Int. Cl.: 5, 42

Service Mark

Trademark

Principal Register

Illimis Therapeutics, Inc. (KOREA, REPUBLIC OF CORPORATION)
2nd, 3rd Fl, 18, Heolleung-ro 569-gil,
Gangnam-gu Seoul
REPUBLIC OF KOREA

CLASS 5: Pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for activating cellular function; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for respiratory organs; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of inflammatory diseases; ophthalmic preparations; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of degenerative brain disease; pharmaceutical preparations for the treatment of brain dysfunction; pharmaceutical preparations for the treatment of stroke; pharmaceutical preparations for the treatment of cerebrovascular disease; pharmaceutical preparations for the treatment of dementia; pharmaceutical preparations for the treatment of Alzheimer's disease; pharmaceutical preparations for use in the treatment of solid tumors and growths, hemolytic diseases and disorders, amyloidosis, metabolic diseases and disorders, lupus, and inflammation and autoimmune diseases and disorders

CLASS 42: Pharmaceutical product development; [pharmaceutical research and development in the field of age-related diseases/disorders and degenerative diseases; pharmaceutical research and development in the field of chronic malady/disease and dysfunction; scientific research in the field of gene therapy;] medical scientific research in the field of brain disease; medical scientific research in the field of neurological diseases; [biotechnology research and scientific and pharmaceutical research in the antibody field;] biological research; [scientific research in the field of cancer disease;] remote monitoring and quality control inspection for others of active substances in the pharmaceutical research field and scientific analysis of active substances in the pharmaceutical research field; research for quality inspection related to human hygiene management for medical research purposes; [scientific and medical research of autoimmune disease;] development of pharmaceutical preparations for cell therapy; stem cell collection for medical research; cell processing and culture for medical research; * pharmaceutical research and development in the field of age-related diseases, disorders and degenerative diseases; pharmaceutical research and development

Katherine Kelly Vidal

Director of the United States
Patent and Trademark Office



in the field of chronic malady, disease and dysfunction; scientific research for medical purpose in the field of gene therapy; biotechnology research; scientific research for medical purpose in the field of cancer disease; medical research of autoimmune disease; * pharmaceutical research and development in the field of inflammatory disease; pharmaceutical research and development in the field of eye disease; pharmaceutical research and development in the field of amyloidosis; * pharmaceutical * consultancy [and information] services relating to pharmaceutical quality control * ; providing information about pharmaceuticals research relating to pharmaceutical quality control *

The color(s) blue, light blue, and yellow is/are claimed as a feature of the mark.

The alphabet "Ill" was expressed with three vertical bars, which is blue, light blue, and yellow. The color part functions as a logo, and the whole including it is pronounced "illimis", the name of the applicant.

The mark consists of the wording "ILLIMIS THERAPEUTICS", in stylized font, with the first letter "I", the letters "IMIS" and "THERAPEUTICS" in blue, the first letter "L" in light blue and the second letter "L" in yellow.

PRIORITY DATE OF 03-07-2022 IS CLAIMED

OWNER OF INTERNATIONAL REGISTRATION 1665604 DATED 03-17-2022, EXPIRES 03-17-2032

No claim is made to the exclusive right to use the following apart from the mark as shown: "THERAPEUTICS"

SER. NO. 79-342,262, FILED 03-17-2022

REQUIREMENTS TO MAINTAIN YOUR FEDERAL TRADEMARK REGISTRATION

WARNING: YOUR REGISTRATION WILL BE CANCELLED IF YOU DO NOT FILE THE DOCUMENTS BELOW DURING THE SPECIFIED TIME PERIODS.

Requirements in the First Ten Years*

What and When to File:

- **First Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) between the 5th and 6th years after the registration date. See 15 U.S.C. §§1058, 1141k. If the declaration is accepted, the registration will continue in force for the remainder of the ten-year period, calculated from the registration date, unless cancelled by an order of the Commissioner for Trademarks or a federal court.
- **Second Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between the 9th and 10th years after the registration date.* See 15 U.S.C. §1059.

Requirements in Successive Ten-Year Periods*

What and When to File:

- You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between every 9th and 10th-year period, calculated from the registration date.*

Grace Period Filings*

The above documents will be accepted as timely if filed within six months after the deadlines listed above with the payment of an additional fee.

***ATTENTION MADRID PROTOCOL REGISTRANTS:** The holder of an international registration with an extension of protection to the United States under the Madrid Protocol must timely file the Declarations of Use (or Excusable Nonuse) referenced above directly with the United States Patent and Trademark Office (USPTO). The time periods for filing are based on the U.S. registration date (not the international registration date). The deadlines and grace periods for the Declarations of Use (or Excusable Nonuse) are identical to those for nationally issued registrations. See 15 U.S.C. §§1058, 1141k. However, owners of international registrations do not file renewal applications at the USPTO. Instead, the holder must file a renewal of the underlying international registration at the International Bureau of the World Intellectual Property Organization, under Article 7 of the Madrid Protocol, before the expiration of each ten-year term of protection, calculated from the date of the international registration. See 15 U.S.C. §1141j. For more information and renewal forms for the international registration, see <http://www.wipo.int/madrid/en/>.

NOTE: Fees and requirements for maintaining registrations are subject to change. Please check the USPTO website for further information. With the exception of renewal applications for registered extensions of protection, you can file the registration maintenance documents referenced above online at <http://www.uspto.gov>.

NOTE: A courtesy e-mail reminder of USPTO maintenance filing deadlines will be sent to trademark owners/holders who authorize e-mail communication and maintain a current e-mail address with the USPTO. To ensure that e-mail is authorized and your address is current, please use the Trademark Electronic Application System (TEAS) Correspondence Address and Change of Owner Address Forms available at <http://www.uspto.gov>.